Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.44 SEK | +2.86% | -1.37% | -45.25% |
Business Summary
Number of employees: 17
Sales per Business
SEK in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Cell Therapies
100.0
%
| 6 | 100.0 % | 10 | 100.0 % | +80.96% |
Sales per region
SEK in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Sweden
100.0
%
| 6 | 100.0 % | 10 | 100.0 % | +80.96% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Mathias Svahn
CEO | Chief Executive Officer | 48 | 14-03-18 |
Edvard Smith
FOU | Founder | 73 | 14-03-18 |
Patrik Fagerholm
DFI | Director of Finance/CFO | 57 | 21-08-31 |
Sofia Sisay
CTO | Chief Tech/Sci/R&D Officer | 43 | 21-12-31 |
Lindsay Davies
CTO | Chief Tech/Sci/R&D Officer | 45 | 19-12-31 |
Corporate Officer/Principal | 38 | 17-12-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | 74 | 14-03-18 | |
Edvard Smith
FOU | Founder | 73 | 14-03-18 |
Camilla Sandberg
BRD | Director/Board Member | 57 | 16-12-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 72,196,998 | 58,524,881 ( 81.06 %) | 0 | 81.06 % |
Company contact information
Sector
1st Jan change | Capi. | |
---|---|---|
-45.25% | 4.56M | |
+20.10% | 46.93B | |
+37.77% | 39.08B | |
-8.55% | 38.48B | |
+29.47% | 31.01B | |
-12.26% | 26.14B | |
+11.77% | 25.88B | |
+34.90% | 12.53B | |
-6.83% | 11.36B | |
-12.82% | 10.65B |
- Stock Market
- Equities
- NXTCL Stock
- Company NextCell Pharma AB